Our approachwas to decrease the inflammatory events associated with the viral infection bytargeting a molecule, Platelet Activating Factor receptor (PAFR), known toinduce several inflammatory events, including leukocyte recruitment and leakage.We found that PAFR deficient mice or wild type mice treated with a PAFRantagonist had less pulmonary inflammation, pulmonary injury and lethality rateswhen infected by two subtypes of Influenza A virus. Here, PTAFR is linked to viral infectious disease.